Alimera Sciences, a privately held ophthalmic
pharmaceutical company, is focused on improving the
delivery of therapeutic agents to enhance patient’s and physician’s ability to manage degenerative eye ailments including diabetic macular edema, age related macular degeneration and glaucoma.

Founded in June 2003, Alimera Sciences was
established behind the principles of doing the right thing
and knowing the right things to do.

Medidur™ (fluocinolone acetonide)
intravitreal insert

Medidur, an innovative new technology by Alimera Sciences and global
drug delivery company pSivida, is currently undergoing global clinical
trials for the treatment of Diabetic Macula Edema (DME).
The FAME (Fluocinolone Acetonide in Diabetic Macular Edema)
Study is tracking results of an innovative new intravitreal
insert that is injected via a 25 gauge transconjunctival
delivery system to slowly release a very low dose of
the corticosteroid fluocinolone acetonide directly into
the vitreous for up to three years.
Learn more about Medidur...